Cabaletta Bio Alternatives & Competitors
12 companies similar to Cabaletta Bio — Engineered T cell therapies designed for the treatment of patients with autoimmu...
Kyverna Therapeutics
Harnessing the power of cell therapy in autoimmune disease.
Emeryville, United States
TRexBio
Decoding Human Tissue Biology to Create Revolutionary Therapeutics
South San Francisco, Unit...
Solid Biosciences
#TogetherWeAreSolid
Boston, United States
Orca Bio
Transforming allogeneic cell therapy for patients with cancer and autoimmune diseases.
Menlo Park, United States
Track all Cabaletta Bio competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Bluejay Therapeutics
Developing innovative cures for infectious diseases with the first target indication of ch...
United States
Vico Therapeutics
Our mission is simple… bring innovative RNA modulating therapies to patients with severe,...
Leiden, The Netherlands
Avidity Biosciences, Inc.
At Avidity, we are developing a new class of oligonucleotide-based therapies.
San Diego, United States
KeifeRx
KeifeRx is a biopharmaceutical company finding disease-modifying treatments for neurodegen...
Mclean, United States
Autolus Therapeutics
Focused on the development of precisely targeted, controlled & highly active T cell therap...
London, United Kingdom
Noa Therapeutics
Noa Therapeutics is transforming the treatment of inflammatory barrier diseases.
Toronto, Canada
Mozart Therapeutics, Inc.
Orchestrating the Immune System
Seattle, United States
Entelexo Biotherapeutics
Entelexo has created a novel platform technology for engineering exosomes as a new approac...
Irvine, United States
About Cabaletta Bio
Engineered T cell therapies designed for the treatment of patients with autoimmune diseases
Development of T cell therapies for autoimmune diseases, Conducting Phase 1/2 clinical trials, CD19 chimeric antigen receptor T cell therapy development, Research and development of CABA® platform
Patients with autoimmune diseases, Healthcare providers specializing in rheumatology, dermatology, and neurology, Biotechnology researchers and collaborators, Investors in biopharmaceuticals
Engineered T Cell Therapies, Autoimmune Diseases, Clinical-stage, CARTA Strategy, CAART Strategy, B Cell-mediated Autoimmune Diseases, CD19-CAR T, Mucosal Pemphigus Vulgaris, MuSK Myasthenia Gravis, Chimeric Antigen Receptor, Autologous CAAR T Cells, Therapeutic Platform, Selective Targeting, Partnership With Penn
B2B, B2D
Product Sales, Licensing, Service Fee
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Cabaletta Bio and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Cabaletta Bio on 9 Jun 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 10 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.